Literature DB >> 27920809

Rates and reasons for lack of persistence with anti-osteoporotic drugs: analysis of the Campania region database.

Giovanni Iolascon1, Francesca Gimigliano2, Antimo Moretti1, Ilaria Riccio1, Massimo Di Gennaro3, Maddalena Illario4, Valeria Marina Monetti5, Valentina Orlando5, Enrica Menditto5.   

Abstract

Subjects with chronic diseases are more likely to be nonpersistent to pharmacological treatment. Lack of persistence is common among subjects using oral anti-osteoporotic drugs, and leads to increased risk of fragility fracture. The aim of our retrospective study is to analyze the rates and reasons for discontinuation of anti-osteoporotic drugs in the Campania Region. Subjects aged over 40 years were included if they had received at least one prescription for any anti-osteoporotic drugs. Data were obtained from an administrative database of regional data on outpatient drug prescriptions reimbursed by the National Health Service. Patients were followed until the discontinuation of anti-osteoporotic therapy or until the end of the observation period. A total of 30,048 were incident users of anti-osteoporotic drugs: 28,317 (94.2%) females. The mean age of the cohort was 69.0±10.0 years. Weekly bis-phosphonates (51.1%) were the most commonly prescribed drugs. In the overall population, persistence rates were 34.8% after 6 months and 13.4% at one year. A multivariate Cox proportional hazard analysis showed that daily regimen (HR 1.9) treatments remained at higher risk of early discontinuation compared to weekly regimen therapies. Our data showed that the persistence to osteoporosis therapy is significantly worse than reported in literature.

Entities:  

Keywords:  anti-osteoporotic drugs; bi-sphosphonates; database; osteoporosis; persistence

Year:  2016        PMID: 27920809      PMCID: PMC5119710          DOI: 10.11138/ccmbm/2016.13.2.127

Source DB:  PubMed          Journal:  Clin Cases Miner Bone Metab        ISSN: 1724-8914


  15 in total

1.  Persistence with calcium and vitamin D in elderly patients after hip fracture.

Authors:  Andrea Giusti; Antonella Barone; Monica Razzano; Mauro Oliveri; Monica Pizzonia; Ernesto Palummeri; Giulio Pioli
Journal:  J Bone Miner Metab       Date:  2008-11-19       Impact factor: 2.626

2.  Medication adherence and fracture risk among patients on bisphosphonate therapy in a large United States health plan.

Authors:  Sally W Wade; Jeffrey R Curtis; Jingbo Yu; Jeffrey White; Bradley S Stolshek; Claire Merinar; Akhila Balasubramanian; Joel D Kallich; John L Adams; Hema N Viswanathan
Journal:  Bone       Date:  2012-01-08       Impact factor: 4.398

3.  Osteoporosis intervention in ambulatory patients with previous hip fracture: a multicentric, nationwide Italian survey.

Authors:  Vincenzo Carnevale; Luciano Nieddu; Elisabetta Romagnoli; Elisabetta Bona; Sara Piemonte; Alfredo Scillitani; Salvatore Minisola
Journal:  Osteoporos Int       Date:  2005-11-09       Impact factor: 4.507

4.  Adherence to bisphosphonate therapy and fracture rates in osteoporotic women: relationship to vertebral and nonvertebral fractures from 2 US claims databases.

Authors:  Ethel S Siris; Steven T Harris; Clifford J Rosen; Charles E Barr; James N Arvesen; Thomas A Abbott; Stuart Silverman
Journal:  Mayo Clin Proc       Date:  2006-08       Impact factor: 7.616

Review 5.  Poor bisphosphonate adherence for treatment of osteoporosis increases fracture risk: systematic review and meta-analysis.

Authors:  I Imaz; P Zegarra; J González-Enríquez; B Rubio; R Alcazar; J M Amate
Journal:  Osteoporos Int       Date:  2009-12-05       Impact factor: 4.507

6.  Determinants of adherence to osteoporosis treatment in clinical practice.

Authors:  M Rossini; G Bianchi; O Di Munno; S Giannini; S Minisola; L Sinigaglia; S Adami
Journal:  Osteoporos Int       Date:  2006-03-15       Impact factor: 4.507

7.  Compliance with pharmacologic therapy for osteoporosis.

Authors:  Robert A Yood; Srinivas Emani; John I Reed; Barbara Edelman Lewis; Mary Charpentier; Eva Lydick
Journal:  Osteoporos Int       Date:  2003-09-19       Impact factor: 4.507

Review 8.  Medication compliance and persistence: terminology and definitions.

Authors:  Joyce A Cramer; Anuja Roy; Anita Burrell; Carol J Fairchild; Mahesh J Fuldeore; Daniel A Ollendorf; Peter K Wong
Journal:  Value Health       Date:  2008 Jan-Feb       Impact factor: 5.725

9.  Fracture outcomes related to persistence and compliance with oral bisphosphonates.

Authors:  Arlene M Gallagher; Stephan Rietbrock; Melvin Olson; Tjeerd P van Staa
Journal:  J Bone Miner Res       Date:  2008-10       Impact factor: 6.741

Review 10.  European guidance for the diagnosis and management of osteoporosis in postmenopausal women.

Authors:  J A Kanis; N Burlet; C Cooper; P D Delmas; J-Y Reginster; F Borgstrom; R Rizzoli
Journal:  Osteoporos Int       Date:  2008-02-12       Impact factor: 4.507

View more
  18 in total

1.  Persistence with denosumab therapy in women affected by osteoporosis with fragility fractures: a multicenter observational real practice study in Italy.

Authors:  S Migliaccio; D Francomano; E Romagnoli; C Marocco; R Fornari; G Resmini; A Buffa; G Di Pietro; S Corvaglia; F Gimigliano; A Moretti; A de Sire; N Malavolta; A Lenzi; E A Greco; G Iolascon
Journal:  J Endocrinol Invest       Date:  2017-06-06       Impact factor: 4.256

2.  Adherence to chronic medication in older populations: application of a common protocol among three European cohorts.

Authors:  Enrica Menditto; Caitriona Cahir; Mercedes Aza-Pascual-Salcedo; Dario Bruzzese; Beatriz Poblador-Plou; Sara Malo; Elisio Costa; Francisca González-Rubio; Antonio Gimeno-Miguel; Valentina Orlando; Przemyslaw Kardas; Alexandra Prados-Torres
Journal:  Patient Prefer Adherence       Date:  2018-10-05       Impact factor: 2.711

3.  Treatment Patterns of Diabetes in Italy: A Population-Based Study.

Authors:  Aida Moreno Juste; Enrica Menditto; Valentina Orlando; Valeria Marina Monetti; Antonio Gimeno Miguel; Francisca González Rubio; María Mercedes Aza-Pascual-Salcedo; Caitriona Cahir; Alexandra Prados Torres; Gabriele Riccardi
Journal:  Front Pharmacol       Date:  2019-08-06       Impact factor: 5.810

Review 4.  Nanopharmaceutics: Part I-Clinical Trials Legislation and Good Manufacturing Practices (GMP) of Nanotherapeutics in the EU.

Authors:  Eliana B Souto; Gabriela F Silva; João Dias-Ferreira; Aleksandra Zielinska; Fátima Ventura; Alessandra Durazzo; Massimo Lucarini; Ettore Novellino; Antonello Santini
Journal:  Pharmaceutics       Date:  2020-02-11       Impact factor: 6.321

5.  Osteosarcopenia in Very Old Age Adults After Hip Fracture: A Real-World Therapeutic Standpoint.

Authors:  Monica Pizzonia; Andrea Casabella; Marta Natali; Lorena Petrocchi; Luca Carmisciano; Alessio Nencioni; Luigi Molfetta; Chiara Giannotti; Gerolamo Bianchi; Andrea Giusti; Federico Santolini; Fiammetta Monacelli
Journal:  Front Med (Lausanne)       Date:  2021-05-20

6.  Prevalence of antibiotic prescription in southern Italian outpatients: real-world data analysis of socioeconomic and sociodemographic variables at a municipality level.

Authors:  Veronica Russo; Valeria Marina Monetti; Francesca Guerriero; Ugo Trama; Antonella Guida; Enrica Menditto; Valentina Orlando
Journal:  Clinicoecon Outcomes Res       Date:  2018-05-03

7.  Geographical Variation in Medication Prescriptions: A Multiregional Drug-Utilization Study.

Authors:  Veronica Russo; Valentina Orlando; Valeria Marina Monetti; Federica Galimberti; Manuela Casula; Elena Olmastroni; Elena Tragni; Enrica Menditto
Journal:  Front Pharmacol       Date:  2020-05-05       Impact factor: 5.810

8.  Persistence at 24 months with denosumab among postmenopausal women with osteoporosis: results of a prospective cohort study.

Authors:  Stuart L Silverman; E Siris; D Belazi; C Recknor; A Papaioannou; J P Brown; D T Gold; E M Lewiecki; G Quinn; A Balasubramanian; S Yue; B Stolshek; D L Kendler
Journal:  Arch Osteoporos       Date:  2018-08-07       Impact factor: 2.617

9.  Predictors of new oral anticoagulant drug initiation as opposed to warfarin in elderly adults: a retrospective observational study in Southern Italy.

Authors:  Francesca Guerriero; Valentina Orlando; Valeria Marina Monetti; Francesca Maria Colaccio; Maurizio Sessa; Cristina Scavone; Annalisa Capuano; Enrica Menditto
Journal:  Ther Clin Risk Manag       Date:  2018-10-08       Impact factor: 2.423

Review 10.  Multiple Cell Signalling Pathways of Human Proinsulin C-Peptide in Vasculopathy Protection.

Authors:  Selma B Souto; Joana R Campos; Joana F Fangueiro; Amélia M Silva; Nicola Cicero; Massimo Lucarini; Alessandra Durazzo; Antonello Santini; Eliana B Souto
Journal:  Int J Mol Sci       Date:  2020-01-18       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.